The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention

British Journal of Clinical Pharmacology

Volumn 61, Issue 5, 2006, Pages 494-501

  Mangoni, A A ^a,c   Jackson, S H D ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Cardiovascular risk; Elderly patients; Primary prevention; Randomized controlled trials; Secondary prevention; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

AGED; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENZYME BLOOD LEVEL; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; META ANALYSIS; MORTALITY; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33646239832     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02609.x     Document Type: Review

References (26)

1. The Scandinavian Simvastatin Survival Study ( S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease Lancet 1994 344 1383 9
2. Sacks FM Pfeffer MA Moye LA Rouleau JL Rutherford JD Cole TG Brown L Warnica JW Arnold JM Wun CC Davis BR Braunwald E The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 1996 335 1001 9
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998 339 1349 57
4. Shepherd J Cobbe SM Ford I Isles CG Lorimer AR MacFarlane PW McKillop JH Packard CJ Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group N Engl J Med 1995 333 1301 7
5. Downs JR Clearfield M Weis S Whitney E Shapiro DR Beere PA Langendorfer A Stein EA Kruyer W Gotto AM Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 1998 279 1615 22
6. Denke MA Grundy SM Hypercholesterolemia in elderly persons: resolving the treatment dilemma Ann Intern Med 1990 112 780 92
7. Shipley MJ Pocock SJ Marmot MG Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study BMJ 1991 303 89 92
8. Weverling-Rijnsburger AW Blauw GJ Lagaay AM Knook DL Meinders AE Westendorp RG Total cholesterol and risk of mortality in the oldest old Lancet 1997 350 1119 23
9. Schatz IJ Masaki K Yano K Chen R Rodriguez BL Curb JD Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study Lancet 2001 358 351 5
10. Lemaitre RN Psaty BM Heckbert SR Kronmal RA Newman AB Burke GL Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study Arch Intern Med 2002 162 1395 400
11. Sever PS Dahlof B Poulter NR Wedel H Beevers G Caulfield M Collins R Kjeldsen SE Kristinsson A McInnes GT Mehlsen J Nieminen M O'Brien E Ostergren J Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 2003 361 1149 58
12. Colhoun HM Betteridge DJ Durrington PN Hitman GA Neil HA Livingstone SJ Thomason MJ Mackness MI Charlton-Menys V Fuller JH Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004 364 685 96
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 360 7 22
14. Shepherd J Blauw GJ Murphy MB Bollen EL Buckley BM Cobbe SM Ford I Gaw A Hyland M Jukema JW Kamper AM MacFarlane PW Meinders AE Norrie J Packard CJ Perry IJ Stott DJ Sweeney BJ Twomey C Westendorp RG Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 2002 360 1623 30
15. Eaton CB Lapane KL Murphy JB Hume AL Effect of statin (HMG-Co-A-Reductase Inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes J Am Geriatr Soc 2002 50 1389 95
16. Higgins M Keller JB Cholesterol, coronary heart disease, and total mortality in middle-aged and elderly men and women in Tecumseh Ann Epidemiol 1992 2 69 76
17. Barrett-Connor E Hypercholesterolemia predicts early death from coronary heart disease in elderly men but not women. The Rancho Bernardo Study Ann Epidemiol 1992 2 77 83
18. Welin L Eriksson H Larsson B Svardsudd K Tibblin G Wilhelmsen L Triglycerides and blood glucose are the major coronary risk factors in elderly Swedish men. The study of men born in 1913 Ann Epidemiol 1992 2 113 9
19. Simons LA Simons J Friedlander Y McCallum J Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years Atherosclerosis 2001 159 201 8
20. Grundy SM Age as a risk factor: you are as old as your arteries Am J Cardiol 1999 83 1455 7 A7
21. Grundy SM Cleeman JI Rifkind BM Kuller LH Cholesterol lowering in the elderly population. Coordinating Committee of the Nationall Cholesterol Education Program Arch Intern Med 1999 159 1670 8
22. LaRosa JC He J Vupputuri S Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 1999 282 2340 6
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) JAMA 2001 285 2486 97
24. Smith SC Jr. Greenland P Grundy SM American Heart Association Conference Proceedings. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary Circulation 2000 101 111 6
25. Greenland P Abrams J Aurigemma GP Bond MG Clark LT Criqui MH Crouse JR III Friedman L Fuster V Herrington DM Kuller LH Ridker PM Roberts WC Stanford W Stone N Swan HJ Taubert KA Wexler L Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden. Writing Group III Circulation 2000 101 E16 E22
26. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice. Summary BMJ 2000 320 705 8